8 completed, 4 unknown, 2 terminated, 1 not yet recruiting. 9 Phase 1, 4 Not applicable, 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 4, Unknown 2, Not yet recruiting 1, Recruiting 1, Terminated 1 |
| Not applicable | 4 | Completed 2, Unknown 2 |
| Phase 2 | 2 | Terminated 1, Unknown 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow Biotrial: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetics, Safety and Tolerability of ITF2357 in Participants With Chronic Hepatic Impairment and With Normal Hepatic Function ITF2357 - Hepatic Impairment | Phase 1 | Completed | Italfarmaco | 24 | 2025-05-29 | 2026-06-18 |
| Study to Evaluate LPH-5 in Healthy Subjects LPH-5, Placebo - Safety Issues, Tolerance | Phase 1 | Not yet recruiting | Lophora | 48 | 2025-04-30 | 2024-12-09 |
| Open-Label Extension of EryDex Study IEDAT-04-2022 Dexamethasone sodium phosphate - Ataxia Telangiectasia | Phase 3 | Terminated | Quince Therapeutics S.p.A. | 101 | 2024-12-11 | 2026-05-05 |
| Safety, Tolerability, and Dose Response of VNA-318 in Healthy Males VNA-318, Placebo - Healthy Volunteer | Phase 1 | Completed | VANDRIA | 92 | 2024-12-03 | 2025-12-10 |
| Evaluate the Neurological Effects of EryDex on Subjects With A-T Dexamethasone sodium phosphate, Placebo - Ataxia Telangiectasia | Phase 3 | Completed | Quince Therapeutics S.p.A. | 105 | 2024-06-24 | 2026-04-30 |
| Phase 1/2a for Safety, PK and PD of SQY51 in Paediatric and Adult Patients Duchenne Muscular Dystrophy Phase 1, SQY51, Phase 2a, SQY51 (cohort 1), Phase 2a, SQY51 (cohort 2) - Duchenne Muscular Dystrophy | Phase 1 / Phase 2 | Unknown | Sqy Therapeutics | 12 | 2023-04-26 | 2024-04-01 |
| Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours EXS21546 - Advanced Solid Tumours | Phase 1 / Phase 2 | Terminated | Exscientia AI Limited | 6 | 2023-04-11 | 2023-11-08 |
| Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors. OMTX705, Pembrolizumab, Tislelizumab (BGB-A317) - Advanced Solid Tumor | Phase 1 | Recruiting | Oncomatryx Biopharma S.L. | 150 | 2022-10-20 | 2025-11-25 |
| Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations Binimetinib 15 MG, Binimetinib 45 MG - Melanoma, BRAF V600 Mutation | Phase 1 | Completed | Pierre Fabre Medicament | 37 | 2022-08-31 | 2024-09-19 |
| Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Bmab 1000 and Prolia® in Normal Healthy Volunteers: DENARIUS: DENosumab Pharmacokinetic equivAlence tRIal in Healthy volUnteerS Bmab 1000, Prolia® - Healthy Volunteers | Phase 1 | Completed | Biocon Biologics UK Ltd | 190 | 2022-03-09 | 2024-04-17 |
| Endocare for Pelvic-perineal Pain Related to Endometriosis Used at Home Endocare, Digital control - Endometriosis, Chronic Pain | Not applicable | Unknown | Lucine | 120 | 2021-12-07 | 2022-01-04 |
| Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations Binimetinib Oral Tablet - Melanoma, BRAF V600 Mutation | Phase 1 | Unknown | Pierre Fabre Medicament | 14 | 2021-09-03 | 2021-12-01 |
| Study of the Effect of an Elastic Compression Medical Device, on Water Balance Change in Healthy Subjects Elastic Compression Prototype - Obstructive Sleep Apnea-hypopnea Syndrome (OSAHS) | Not applicable | Completed | Laboratoires Innothera | 38 | 2021-03-23 | 2021-06-07 |
| Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients. Cognitive assessment of obsessive-compulsive and impulsive behaviours, Genomic analysis, Glucoregulation assessment - Romano-Ward Syndrome, Long QT Syndrome | Not applicable | Unknown | Biotrial | 100 | 2021-01-08 | 2021-01-20 |
| Validating Reward-related Biomarkers (RTOC) Self-rating Questionnaires, Measures of Reward processing/reinforcement learning, Additional Schizophrenia-specific Questionnaires and Interviews - Schizophrenia, Depression | Completed | Maastricht University | 160 | 2019-09-16 | 2022-07-26 | |
| Study of the Effect of Elastic Compression (French Class III) on Water Balance Change in Healthy Subjects Compression stocking, No use of compression stocking - Healthy Subjects | Not applicable | Completed | Laboratoires Innothera | 23 | 2016-07-01 | 2016-08-24 |
Ataxia Telangiectasia (2) · Melanoma (2) · Anhedonia (1) · Chronic Pain (1) · Compulsive Behavior (1) · Depression (1) · Endometriosis (1) · Long QT Syndrome (1) · Muscular Dystrophy, Duchenne (1) · Pelvic Pain (1) · Romano-Ward Syndrome (1) · Schizophrenia (1) · Sleep Apnea, Obstructive (1)
binimetinib (2) · dexamethasone 21-phosphate (2) · Clinical Trials, Phase I as Topic (1) · Denosumab (1) · Interviews as Topic (1) · Patents as Topic (1) · Stockings, Compression (1) · givinostat (1) · givinostat hydrochloride (1) · pembrolizumab (1) · tislelizumab (1)
France (10) · Spain (4) · United States (4) · Germany (3) · Denmark (2) · Italy (2) · Norway (2) · Poland (2) · Switzerland (2) · United Kingdom (2) · Belgium (1) · Bulgaria (1) · Greece (1) · Netherlands (1)
Dirk Thye, MD (2) · Marina Klein, MD (2) · Sophie Hays, MD (2) · Antoine Italiano, MD (1) · Dennis Hernaus, PhD (1) · Hakim Charfi, MD (1) · Klaus Dugi, MD (1) · Probst Vincent, MD (1)
PMID 26142081, PMID 28083030, PMID 33250788, PMID 37260160, PMID 42600624, PMID 42643157